Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 20
- Registration Number
- NCT04454762
- Locations
- 🇩🇪
Department of Internal Medicine I, Johannes Gutenberg University Mainz, Mainz, Germany
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 575
- Registration Number
- NCT04446117
- Locations
- 🇺🇸
Exelixis Clinical Site #6, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #18, Philadelphia, Pennsylvania, United States
🇵🇱Exelixis Clinical Site #243, Otwock, Mazowieckie, Poland
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 69
- Registration Number
- NCT04427787
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 100
- Registration Number
- NCT04416646
- Locations
- 🇮🇹
Istituto Oncologico Veneto, Padova, Italy
Cabozantinib in High Grade Neuroendocrine Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 32
- Registration Number
- NCT04412629
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Bradley A. McGregor, MD
- Target Recruit Count
- 60
- Registration Number
- NCT04413123
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical, Dallas, Texas, United States
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 522
- Registration Number
- NCT04338269
- Locations
- 🇺🇸
Texas Oncology - Central South, Austin, Texas, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 48
- Registration Number
- NCT04322955
- Locations
- 🇺🇸
The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 25
- Registration Number
- NCT04316182
- Locations
- 🇪🇸
Hospital Puerta de Hierro, Madrid, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Deepak Kilari
- Target Recruit Count
- 46
- Registration Number
- NCT04289779
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.